Mitochondrial / Barth syndrome

SS-31

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as Elamipretide, MTP-131, Forzinity

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

SS-31 is listed in the ezGLP knowledgebase under Mitochondrial / Barth syndrome. Evidence and regulatory status can vary by formulation, route, and jurisdiction.

Category: Mitochondrial / Barth syndrome
Routes represented: Subcutaneous (SubQ)
Approximate library half-life: 4 hours; formulation-dependent and not dosing guidance
Storage context: Refrigerate Forzinity at 2–8°C; do not freeze. Follow the product label; opened vials are discarded after 8 days.

Published literature

No validated PubMed or DOI link is currently curated for this entry.

Safety evidence

Common or reported: injection-site redness, pain, firmness, itching, or bruising, eosinophilia.

Serious or important: hypersensitivity.

The approved Barth-syndrome safety dataset was small.

Safety evidence source

Interaction evidence

These are general, pairwise evidence notes. Green identifies the potential-synergy category, while Lv3/Lv2/Lv1 communicates evidence strength; it does not guarantee benefit or cancel a safety warning.

With NAD+

Complementary evidenceLv1

SS-31 plus the NAD+ precursor NMN produced complementary cardiac effects in aged mice, providing an indirect rationale for interest in SS-31 with NAD+.

Interaction evidence sourceNAD+ evidence reviewElamipretide label

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.